Dapagliflozin/saxagliptin/metformin
Dapagliflozin/saxagliptin/metformin, sold under the brand name Qternmet XR among others, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin, saxagliptin, and metformin. It is taken by mouth. The drug is marketed by AstraZeneca.

The most common side effects include infections of the nose and throat, hypoglycaemia (low blood sugar) when used with a sulphonylurea and effects on the gut such as nausea (feeling sick), vomiting, diarrhoea, abdominal (tummy) pain and loss of appetite.

Dapagliflozin/saxagliptin/metformin was approved for medical use in the United States in May 2019, and in the European Union in November 2019. Its marketing authorisation was withdrawn in the European Union in August 2020, and its approval was withdrawn in the US in April 2021, in both cases at the request of AstraZeneca.
Q1779868
fixed-dose combination
Concept
Q575062
anti-diabetic medication
Concept
Q1100933
glycemic control
Concept
Q3025883
type 2 diabetes
Concept
Q409898
dapagliflozin
Concept
Q3121121
saxagliptin
Concept
Q19484
metformin
Concept
Q731938
AstraZeneca
ORG
Q104843716
Dapagliflozin/saxagliptin/metformin
UNK
Q104843716
Dapagliflozin/saxagliptin/metformin
UNK
2019-05-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
May 2019
DATE
2019-11-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
November 2019
DATE
2020-08-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
August 2020
DATE
2021-04-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
April 2021
DATE
+2^^http://www.w3.org/2001/XMLSchema#decimal
2
NUMBER
use